中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(1): 74-79

Serological characteristics of individuals with hepatitis C virus/hepatitis B virus overlapping infection

DOI: 10.12449/JCH260109
  • 1.

    Department of Geriatrics，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

  • 2.

    Department of Critical Care Medicine，Heyou Hospital of Shunde District，Foshan，Guangdong 528306，China

Research funding:

National Clinical Research Center for Geriatric Diseases (NCRCG-PLAGH-2024015);

The Construction Project of Infectious Diseases Diagnosis and Treatment Base for Important Health Care Objects in the “14th Five Year Plan” of Military Health Care 

More Information
  • Corresponding author: CHENG Yongqian， chengyq302@126.com （ORCID： 0000-0001-6832-6419）
  • Received Date: 2025-06-30
  • Accepted Date: 2025-09-29
  • Published Date: 2026-01-25
    Abstract
  •   Objective  To investigate the status of overlapping hepatitis B virus （HBV） infection in patients with chronic hepatitis C virus （HCV） infection and the serological characteristics of such patients.  Methods  A total of 8 637 patients with HCV infection who were hospitalized from January 1， 2010 to December 31， 2020 and had complete data of HBV serological markers were enrolled， and the composition ratio of patients with overlapping HBV serological markers was analyzed among the patients with HCV infection. The patients were divided into groups based on age and year of birth， and serological characteristics were analyzed， and the distribution of HBV-related serological characteristics were analyzed across different HCV genotypes.  Results  The patients with HCV/HBV overlapping infection accounted for 5.85%， and the patients with previous HBV infection accounted for 48.10%； the patients with protective immunity against HBV accounted for 14.67%， while the patients with a lack of protective immunity against HBV accounted for 31.39%. The patients were divided into groups based on age： in the 0 — 17 years group， the patients with protective immunity against HBV accounted for 61.41% （304 patients）； the 18 — 44 years group was mainly composed of patients with previous HBV infection （698 patients， 37.31%）， the 45 — 59 years group was predominantly composed of patients with previous HBV infection （1 945 patients， 50.38%）， and the ≥60 years group was also predominantly composed of patients with previous HBV infection （1 486 patients， 61.66%）. The patients were divided into groups based on the year of birth： in the pre-1992 group， the patients with previous HBV infection accounted for 51.63% （4 112 patients）； in the 1992 — 2005 group， the patients with protective immunity against HBV accounted for 54.72% （168 patients）； in the post-2005 group， the patients with protective immunity against HBV accounted for 64.38% （235 patients）. In this study， 6 301 patients underwent HCV genotype testing： the patients with genotype 1b accounted for the highest proportion of 51.71% （3 258 patients）， followed by those with genotype 2a （1 769 patients， 28.07%）， genotype 3b （63 patients， 1.00%）， genotype 3a （10 patients， 0.16%）， genotype 4 （21 patients， 0.33%）， and genotype 6a （5 patients， 0.08%）.  Conclusion  With the implementation of hepatitis B planned vaccination program in China， there has been a significant reduction in the proportion of patients with previous HBV infection among the patients with HCV/HBV overlapping infection， but there is still a relatively high proportion of patients with a lack of protective immunity against HBV.

     

    • FullText(HTML)
  • loading
    • References(33)
  • [1]
    LIU ZH, HOU JL. Hepatitis B virus(HBV) and hepatitis C virus(HCV) dual infection[J]. Int J Med Sci, 2006, 3( 2): 57- 62. DOI: 10.7150/ijms.3.57.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for prevention and treatment of chronic hepatitis B(2022 Edition)[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2022 Edition)[J]. Chin J Infect Dis, 2023, 41( 1): 29- 46. DOI: 10.3760/cmaj.cn311365-20230217-00045.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 29- 46. DOI: 10.3760/cma.j.cn311365-20230217-00045.
    [4]
    World Health Organization. 1.3 million people die from viral hepatitis every year![EB/OL].( 2024-04-21)[ 2025-03-06]. https://www.163.com/dy/article/J0N5E1OK0552ZA4S.html. https: //www.163.com/dy/article/J0N5E1OK0552ZA4S.html
    [5]
    SAYED D, BAKRY R, MIKHAIL N, et al. The prevalence of infection and potential risk factors for HBV and HCV among healthcare workers not vaccinated against HBV: A study from a cancer center in Egypt, 2021-2022[J]. Arab J Gastroenterol, 2025, 26( 2): 201- 206. DOI: 10.1016/j.ajg.2025.01.013.
    [6]
    YANG J, RAO HY. EASL recommendations on treatment of hepatitis C: Final update of the series(2020)[J]. J Clin Hepatol, 2020, 36( 12): 2681- 2687. DOI: 10.3969/j.issn.1001-5256.2020.12.009.

    杨甲, 饶慧瑛. 2020年欧洲肝病学会推荐意见: 丙型肝炎的治疗(最终更新版)[J]. 临床肝胆病杂志, 2020, 36( 12): 2681- 2687. DOI: 10.3969/j.issn.1001-5256.2020.12.009.
    [7]
    XIE YD, FENG B, RAO HY. Interpretation of guidelines for the prevention and treatment of chronic hepatitis B(2022 edition)[J]. J Clin Hepatol, 2023, 39( 7): 1553- 1559. DOI: 10.3969/j.issn.1001-5256.2023.07.007.

    谢艳迪, 封波, 饶慧瑛.《慢性乙型肝炎防治指南(2022年版)》解读[J]. 临床肝胆病杂志, 2023, 39( 7): 1553- 1559. DOI: 10.3969/j.issn.1001-5256.2023.07.007.
    [8]
    MAVILIA MG, WU GY. HBV-HCV coinfection: Viral interactions, management, and viral reactivation[J]. J Clin Transl Hepatol, 2018, 6( 3): 296- 305. DOI: 10.14218/JCTH.2018.00016.
    [9]
    Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on prevention of hepatitis B virus reactivation after allogeneic hematopoietic stem cell transplantation(2023)[J]. Chin J Hematol, 2023, 44( 6): 441- 448. DOI: 10.3760/cma/j.issn.0253-2727.2023.06.001.

    中华医学会血液学分会造血干细胞应用学组. 异基因造血干细胞移植后防治乙型肝炎病毒再激活中国专家共识(2023年版)[J]. 中华血液学杂志, 2023, 44( 6): 441- 448. DOI: 10.3760/cma.j.issn.0253-2727.2023.06.001.
    [10]
    DANG RB, ZHANG SX, ZHANG WD, et al. Assessment for immune effectiveness of hepatitis B vaccination among infant population in China[J]. Chin J Public Health, 2009, 25( 4): 385- 387. DOI: 10.3321/j.issn: 1001-0580.2009.04.001.

    党如波, 张顺祥, 张卫东, 等. 中国新生儿乙肝疫苗免疫效果评估[J]. 中国公共卫生, 2009, 25( 4): 385- 387. DOI: 10.3321/j.issn: 1001-0580.2009.04.001.
    [11]
    RAZAVI-SHEARER D, KONDILI L, HALL S, et al. WED-034 Prevalence of HBV and HCV among migrants in EU-27: The impact of the Ukrainian refugee crisis[J]. J Hepatol, 2025, 82: S695- S696. DOI: 10.1016/S0168-8278(25)01837-9.
    [12]
    LIU YQ, YANG F, LI L, et al. Study on the overlapping infection of hepatitis B and hepatitis C in Shandong Province[J]. Chongqing Med, 2018, 47( 10): 1389- 1391. DOI: 10.3969/j.issn.1671-8348.2018.10.026.

    刘义庆, 杨帆, 李丽, 等. 山东地区人群乙型肝炎和丙型肝炎重叠感染情况研究[J]. 重庆医学, 2018, 47( 10): 1389- 1391. DOI: 10.3969/j.issn.1671-8348.2018.10.026.
    [13]
    LI FY, FENG Y, LIU X, et al. HBV and HCV co-infection in Chinese newly diagnosed HIV+ subjects in 2015 and 2023: A cross-sectional study[J]. Pathogens, 2024, 13( 5): 367. DOI: 10.3390/pathogens13050367.
    [14]
    DESIKAN P, RANGNEKAR A, KHAN Z, et al. Sero-occurrence of HBV/HCV co-infection and levels of liver enzymes among patients at a tertiary care hospital in central India: A pilot study[J]. Cent Asian J Glob Health, 2019, 8( 1): 313. DOI: 10.5195/cajgh.2019.313.
    [15]
    WANG L, LIU N, YANG H, et al. Analysis on epidemic trend and spatio-temporal clustering of hepatitis B in China from 2006 to 2020[J]. Chin J Epidemiol, 2025, 46( 3): 410- 417. DOI: 10.3760/cma.j.cn112338-2024-1031-00676.

    王磊, 刘娜, 杨宏, 等. 2006—2020年中国乙型肝炎流行趋势和时空聚集性分析[J]. 中华流行病学杂志, 2025, 46( 3): 410- 417. DOI: 10.3760/cma.j.cn112338-20241031-00676.
    [16]
    WANG X, PAN F. China still faces great challenges in eliminating hepatitis B[J]. China Mod Med, 2025, 32( 2): 1- 3. DOI: 10.3969/j.issn.1674-4721.2025.02.002.

    王霞, 潘锋. 我国消除乙肝仍面临巨大挑战[J]. 中国当代医药, 2025, 32( 2): 1- 3. DOI: 10.3969/j.issn.1674-4721.2025.02.002.
    [17]
    ZAMANI K, ROSTAMI P, DAREHBAGH RR, et al. Hepatitis B and C virus infection and risk of multiple myeloma: A systematic review and meta-analysis[J]. BMC Cancer, 2025, 25( 1): 998. DOI: 10.1186/s12885-025-14420-5.
    [18]
    ZARĘBSKA-MICHALUK D, BRZDĘK M, RZYMSKI P, et al. Hepatitis B virus coinfection in patients treated for chronic hepatitis C: Clinical characteristics, risk of reactivation with long-term follow-up, and effectiveness of antiviral therapy[J]. Pol Arch Intern Med, 2024, 134( 1): 16638 DOI: 10.20452/pamw.16638.
    [19]
    DECORSIÈRE A, MUELLER H, van BREUGEL PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J]. Nature, 2016, 531( 7594): 386- 389. DOI: 10.1038/nature17170.
    [20]
    AWADH AA, ALHARTHI AA, ALGHAMDI BA, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Systematic review and meta-analysis[J]. J Glob Infect Dis, 2024, 16( 4): 127- 134. DOI: 10.4103/jgid.jgid_211_23.
    [21]
    ZHOU DQ, LIU JY, ZHAO F, et al. Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long study[J]. World J Gastrointest Oncol, 2024, 16( 12): 4625- 4635. DOI: 10.4251/wjgo.v16.i12.4625.
    [22]
    HUANG M, WANG DY, HUANG J, et al. Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens[J]. Nat Commun, 2025, 16( 1): 5360. DOI: 10.1038/s41467-025-60894-z.
    [23]
    SAJID MS, VARGHESE RS, KROEMER A, et al. Low-abundance serum protein biomarker candidates for HCC in patients with liver cirrhosis[J]. J Proteome Res, 2025, 24( 7): 3656- 3665. DOI: 10.1021/acs.jproteome.5c00231.
    [24]
    YAN LB, RAO HY, MA YJ, et al. Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: Prevalence, clinical characteristics, viral interactions and host genotypes: A nationwide cross-sectional study[J]. BMJ Open, 2016, 6( 10): e012016. DOI: 10.1136/bmjopen-2016-012016.
    [25]
    WANG N, ZHAO SM, CHENG Q, et al. Meta-analysis of the association between super infection of HBV, HCV and primary liver cancer in China[J]. J Mod Oncol, 2015, 23( 15): 2169- 2172. DOI: 10.3969/j.issn.1672-4992.2015.15.027.

    王宁, 赵四敏, 程琦, 等. 我国HBV、HCV重叠感染与原发性肝癌关系的Meta分析[J]. 现代肿瘤医学, 2015, 23( 15): 2169- 2172. DOI: 10.3969/j.issn.1672-4992.2015.15.027.
    [26]
    CHEN Y, YU CS, YIN XR, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China[J]. Emerg Microbes Infect, 2017, 6( 11): e95. DOI: 10.1038/emi.2017.77.
    [27]
    RAO HY, WEI L, LOPEZ-TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2014, 29( 3): 545- 553. DOI: 10.1111/jgh.12398.
    [28]
    ZHANG B, WANG RY, XIAO JY, et al. Genotype distribution characteristics of HCV infection in voluntary blood donors in Ankang area[J]. Clin Res Pract, 2023, 8( 33): 6- 9. DOI: 10.19347/j.cnki.2096-1413.202333002.

    张博, 王儒意, 肖金玉, 等. 安康地区无偿献血人群HCV感染的基因型分布特征[J]. 临床医学研究与实践, 2023, 8( 33): 6- 9. DOI: 10.19347/j.cnki.2096-1413.202333002.
    [29]
    MU CY, ZHANG XM, FAN DS, et al. Analysis of HCV genotype distribution and natural drug resistance mutation in Huaibei city[J]. J Bengbu Med Coll, 2023, 48( 2): 260- 263. DOI: 10.13898/j.cnki.issn.1000-2200.2023.02.029.

    木朝宇, 张晓梅, 范德胜, 等. 淮北市HCV感染者基因亚型分布特征及1b型天然耐药突变分析[J]. 蚌埠医学院学报, 2023, 48( 2): 260- 263. DOI: 10.13898/j.cnki.issn.1000-2200.2023.02.029.
    [30]
    TANG Q, CHEN ZW, LI H, et al. Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Chinese mainland and a phylogenetic analysis[J]. Infect Dis Poverty, 2023, 12( 1): 66. DOI: 10.1186/s40249-023-01106-y.
    [31]
    WEN XY, TANG M, DENG ZH, et al. Distribution and clinical features of HCV genotypes in three areas in southwest China[J]. China J Mod Med, 2016, 26( 23): 42- 46. DOI: 10.3969/j.issn.1005-8982.2016.23.009.

    温先勇, 唐敏, 邓正华, 等. 中国西南三地HCV基因型的分布及临床特征[J]. 中国现代医学杂志, 2016, 26( 23): 42- 46. DOI: 10.3969/j.issn.1005-8982.2016.23.009.
    [32]
    TENG Y, XU ZC, ZHAO KT, et al. Novel function of SART1 in HNF4α transcriptional regulation contributes to its antiviral role during HBV infection[J]. J Hepatol, 2021, 75( 5): 1072- 1082. DOI: 10.1016/j.jhep.2021.06.038.
    [33]
    KANDA T, LAU GKK, WEI L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation[J]. Hepatol Int, 2019, 13( 6): 649- 661. DOI: 10.1007/s12072-019-09988-7.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (64) PDF downloads(38) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return